Want to connect with a local rep or request a demo pen?
Access Additional Start Resources ||| h3
https://main--ewi-mounjaro-aem-us--elilillyco.aem.page/fragments/forms/getting-patients-started
By providing my professional information, I agree that it may be used by Eli Lilly and Company ("Lilly") and its affiliates and partners or third parties, working on Lilly's behalf, for Lilly's marketing or promotional purposes. I may unsubscribe/opt-out by clicking the unsubscribe link within any email I receive or by calling 1-800-LILLYRX (1-800-545-5979). For more information about Lilly's privacy practices, please view the Privacy Statement and Consumer Health Privacy Notice.
How to Prescribe Mounjaro | prescribing
Help get patients started on Mounjaro1
Start
Provide patients with a 1-month* 2.5 mg starting dose prescription
The 2.5-mg dose is for treatment initiation and is not intended for glycemic control.
Prescribe
After 4 weeks on the 2.5 mg dose, provide patients with a 1-month* or 3-month† 5.0-mg prescription
Activate
Help your eligible patients save on Mounjaro
For eligible, commercially insured patients with Mounjaro coverage, Governmental beneficiaries excluded, terms and conditions apply
Prior authorizations are common for the incretin therapies. Get tips for Prior Authorization Submission Process. ||| h3
†Three months is defined as 84 days and up to 12 pens.
See Savings Card Terms and Conditions 2.5-mg dose NDC: 0002-1506-80; 5-mg dose NDC: 0002-1495-80
How to Dose Mounjaro | dosing
Multiple doses for customizable glycemic control1‡
START THE EXPERIENCE
Starting dose (for 4 weeks)
Month 1
CONTINUE THE EXPERIENCE
For at least 4 weeks
Month 2
IF ADDITIONAL GLYCEMIC CONTROL IS NEEDED
For at least 4 weeks
For at least 4 weeks
For at least 4 weeks
Maximum dose
‡Consider patient history and monitor for tolerability and side effects.
Patient Start Resources | patient-expectation
Tips and resources for you and your staff
Getting Started Video
A video guide on initiating treatment, dosing options and what to expect with side effects
Resources for your patients | patient-resources
Digital Starter Kit ||| h3
Tell your patients to text MJ to 85099 to download a free kit to help them get started on Mounjaro.
The kit provides tips on starting Mounjaro, what to expect, reminder options and additional resources.
Download Patient Brochure ||| h3
The brochure provides additional tips to starting Mounjaro, what to expect, reminder options and additional resources.
Download Savings Card ||| h3
Download a savings card for your eligible, commercially insured patients with Mounjaro coverage.*
*Governmental beneficiaries excluded, terms and conditions apply

Discover Lilly Play
Watch videos about Mounjaro and how to help your patients get started.
Select Important Safety Information: ||| h6
Risk of Thyroid C-cell Tumors ||| lifestyle-purple
Counsel patients regarding the potential risk for MTC with the use of Mounjaro and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Mounjaro. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
References:
- Mounjaro. Prescribing Information. Lilly USA, LLC.
